Human epidermal growth factor receptor 2 (HER2)-targeted therapy, i.e., trastuzumab, a class of medicines used to treat all stages of HER2-positive breast cancer, has also been associated with cardiotoxicity (Table 1). This evidence concerns the gene ERBB2 and breast cancer.